IRTC — iRhythm Holdings, Inc.

Is IRTC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Neutral As of November 17, 2026

iRhythm Holdings, Inc. (IRTC) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $90.83. The rating moved from Oversold to Neutral on November 16, 2026.

AI analysis

iRhythm Holdings, Inc. (IRTC) is a leader in ambulatory cardiac monitoring with a differentiated patch + analytics service offering that drives recurring revenue and high diagnostic yield. The company stands to benefit from a large addressable market for arrhythmia detection, continued clinical validation and improving operating leverage as utilization grows. Near‑term catalysts include ongoing reimbursement adoption, new clinical readouts, and continued commercial scale. Key constraints include payer/reimbursement risk, competition from consumer wearables and new entrants, regulatory/data‑privacy exposures, and execution risks around margin expansion and product diversification. Market tone over the recent session has been measured rather than volatile, which should allow investors to focus on company fundamentals and pipeline developments over the coming weeks.

Key factors

  • Proprietary ambulatory cardiac monitoring platform (Zio) with differentiated long‑duration patch and analytics that create recurring, service‑like revenue streams
  • Large and growing addressable market driven by aging populations, rising arrhythmia screening, and demand for remote diagnostics
  • Improving unit economics and operating leverage potential as utilization scales and fixed costs are absorbed
  • Ongoing reimbursement wins and clinical evidence supporting diagnostic yield, which support revenue visibility and payer acceptance
  • Limited near‑term macro volatility and measured market tone allow focus on fundamentals and earnings follow‑through

Risks

  • Reimbursement pressure or adverse payer coverage decisions that reduce average revenue per study
  • Competition from consumer wearables (e.g., Apple, Fitbit) and new entrants with lower‑cost monitoring alternatives
  • Regulatory or data‑privacy issues around medical device/software that could slow adoption or require costly remediation
  • Execution risk: scaling operations, managing costs, and converting clinical trials/awareness into sustainable revenue growth
  • Dependence on a relatively concentrated product portfolio; slower product diversification would expose performance to single‑product risk
  • Political/regulatory shifts in Medicare Advantage and broader healthcare policy that could alter payment dynamics

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for IRTC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.